Literature DB >> 2294100

Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells.

S W Lin1, K J Smith, D Welsch, D W Stafford.   

Abstract

Human blood clotting factor IX, and two chimeric molecules of factor IX, in which the first epidermal growth factor-like domain or both epidermal growth factor-like domains have been replaced by that of human factor X, have been expressed in mouse C127 cells. The recombinants have been purified using a metal ion-dependent monoclonal antibody specific for residues 1-42 of human factor IX. All recombinant molecules are activated normally by human factor XIa in the presence of calcium ion. Activation of the factor IX recombinants by factor VIIa-tissue factor appears to be normal for the epidermal growth factor-1 exchange but considerably reduced for the construction containing both epidermal growth factor-like domains of factor X. The analysis of gamma-carboxyglutamic acid residues reveals that all of the purified recombinants are almost fully carboxylated. The extent of aspartic acid hydroxylation at residue 64 is 60% for all recombinants. The chimeric molecule with both epidermal growth factor-like domains from factor X has about 4% normal activity in the activated partial thromboplastin time assay. In contrast, the construct containing the first epidermal growth factor-like domain of factor X shows essentially normal clotting activity. Thus, it is unlikely that this domain is involved in a unique interaction with factor VIII.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294100

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study.

Authors:  Divi Venkateswarlu
Journal:  Biochem Biophys Res Commun       Date:  2014-08-23       Impact factor: 3.575

3.  Determinants of the factor IX mutational spectrum in haemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein.

Authors:  A I Wacey; M Krawczak; V V Kakkar; D N Cooper
Journal:  Hum Genet       Date:  1994-12       Impact factor: 4.132

4.  X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

Authors:  H Brandstetter; M Bauer; R Huber; P Lollar; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

5.  The role of the second growth-factor domain of human factor IXa in binding to platelets and in factor-X activation.

Authors:  S S Ahmad; R Rawala; W F Cheung; D W Stafford; P N Walsh
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

6.  Contribution of the NH2-terminal EGF-domain of factor IXa to the specificity of intrinsic tenase.

Authors:  Shabir H Qureshi; Likui Yang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

7.  Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin.

Authors:  R Drews; R K Paleyanda; T K Lee; R R Chang; A Rehemtulla; R J Kaufman; W N Drohan; H Luboń
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.

Authors:  D Zhong; K J Smith; J J Birktoft; S P Bajaj
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.